During the past decade, Great Lakes Clinical Trials at Ravenswood Rheumatology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Great Lakes Clinical Trials at Ravenswood Rheumatology" are "Chronic Gout" (1 trials) and "Respiratory Syncytial Virus Infections" (1 trials). Many other conditions were trialed in "Great Lakes Clinical Trials at Ravenswood Rheumatology" in a lesser frequency.

Most popular intervention types in "Great Lakes Clinical Trials at Ravenswood Rheumatology" are "Biological" (1 trials), "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "MVA-BN-RSV vaccine" (1 trials), "Placebo" (1 trials), "SEL-212A" (1 trials), "SEL-212B" (1 trials) and "Tris Buffered Saline (TBS)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Great Lakes Clinical Trials at Ravenswood Rheumatology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Great Lakes Clinical Trials at Ravenswood Rheumatology". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Great Lakes Clinical Trials at Ravenswood Rheumatology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Great Lakes Clinical Trials at Ravenswood Rheumatology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".